Royalty Pharma (RPRX) Equity Income (2019 - 2026)

Royalty Pharma has disclosed Equity Income across 8 years of filings, most recently posting -$20.2 million for Q1 2026.

• Equity Income for Q1 2026 came in at -$20.2 million, up 56.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (up 538.94% YoY), and the FY2025 annual result was $29.1 million, down 26.45% from the prior year.
• Equity Income came in at -$20.2 million for Q1 2026 at Royalty Pharma, down from $4.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $77.7 million in Q1 2024 to a low of -$47.1 million in Q2 2024.
• The 5-year median for Equity Income is $397000.0 (2022), against an average of $3.8 million.
• Peak annual rise in Equity Income reached 15417.91% in 2024, while the deepest fall reached 6020.0% in 2024.
• Royalty Pharma's Equity Income stood at -$10.5 million in 2022, then surged by 102.56% to $268000.0 in 2023, then soared by 15417.91% to $41.6 million in 2024, then sank by 90.37% to $4.0 million in 2025, then slumped by 603.52% to -$20.2 million in 2026.
• The last three Equity Income figures came in at -$20.2 million (Q1 2026), $4.0 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.